西洛多辛治疗良性前列腺增生患者夜尿症的多中心IV期试验
本研究为12周、单臂、开放标签、前瞻性、多中心IV期试验,纳入50岁以上、夜尿≥2次/夜且IPSS≥8的BPH男性,每日服用西洛多辛8mg。药物不良反应发生率11.8%,最常见为射精障碍(7.6%),无严重不良反应。
要点
- 西洛多辛8mg每日一次治疗12周可显著减少BPH患者夜尿次数。
- IPSS、OABSS及ICIQ-N评分均随治疗显著改善。
- 药物不良反应率11.8%,射精障碍最常见(7.6%),无严重不良反应。
核心结论
- 西洛多辛治疗BPH患者夜尿症安全有效。
研究设计与样本
- 12周、单臂、开放标签、前瞻性、多中心IV期试验。
- 纳入50岁以上、夜尿≥2次/夜、IPSS≥8且QoL≥3的BPH男性。
- 安全性分析118例,全分析集112例。
- 患者每日服用西洛多辛8mg,共12周。
主要发现
- 药物不良反应发生率为11.8%,最常见为射精障碍(7.6%)。
- 未报告严重不良反应。
临床怎么用
- 对于BPH合并夜尿症且IPSS≥8、QoL≥3的50岁以上男性,可考虑使用西洛多辛8mg每日一次治疗。
- 用药期间需关注射精障碍等不良反应。
局限性
- 单臂、开放标签设计,缺乏对照组。
- 样本量有限(安全性分析118例,全分析集112例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: This was a 12-week, single-arm, open-label, prospective, multicenter study. The study included men aged 50 years or older with nocturia (≥2 events/night) based on a voiding diary, an International Prostate Symptom Score (IPSS) ≥8, and a quality of life score ≥3. Enrolled patients received 8 mg of silodosin once daily for 12 weeks. We evaluated changes in the mean number of nocturia episodes (using a voiding diary) from baseline to the final assessment. Safety assessments included the rate of adverse events and adverse drug reactions. RESULTS: There were 118 patients included in the safety evaluation analysis, and 112 patients in the full analysis set group. The number of nocturia episodes decreased significantly after 12 weeks of treatment with silodosin (-1.12 ± 1.05, P < .0001). The secondary efficacy variables, including IPSS, overactive bladder symptom score and International Consultation on Incontinence Questionnaire-Nocturia score, also improved with treatment (P < .0001). There were abnormal drug reactions in 11.8% of patients. The most common adverse drug reaction was an ejaculatory disorder (7.6%). There were no significant adverse drug reactions reported. CONCLUSION: Silodosin was found to be safe and effective in the treatment of nocturia in patients with BPH.
引用
- Cho KJ, Lee JZ, Song YS, et al. Evaluating the Efficacy and Safety of Silodosin on Nocturia in Patients With Benign Prostatic Hyperplasia: A Multicenter, Prospective, Open-label, Single-arm, Phase IV Trial. Urology. 2018. PMID: 30098325. doi:10.1016/j.urology.2018.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。